Potential cardioprotective effect of mibefradil in the long-term treatment of hypertension

Cardiology

Volumn 89, Issue SUPPL. 1, 1998, Pages 16-22

  Waeber, Bernard ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Antihypertensive treatment; Calcium antagonist; Calcium channels; Coronary heart disease; L type calcium channel; Mibefradil; T type calcium channel

Indexed keywords

CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; MIBEFRADIL;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; HEART PROTECTION; HEART RATE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INOTROPISM; ISCHEMIC HEART DISEASE; LEG EDEMA; LONG TERM CARE; MORTALITY; PRIORITY JOURNAL;

BENZIMIDAZOLES; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; CORONARY DISEASE; DRUG INTERACTIONS; FOLLOW-UP STUDIES; HEART RATE; HUMANS; HYPERTENSION; MIBEFRADIL; SAFETY; TETRAHYDRONAPHTHALENES; TREATMENT OUTCOME;

EID: 0031889327     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000047275     Document Type: Conference Paper

References (34)

1. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J: Blood pressure, stroke, and coronary heart disease. 1. Prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765-774.
2. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH: Blood pressure, stroke and coronary heart disease. 2. Short-term reductions in blood pressure: Overview of randomized drug trials in their epidemiological context. Lancet 1990;335:827-838.
3. Hansson L: The key issues in preventive cardiology. Blood Press 1992;1(suppl 4):7-10.
4. Ferrari P, Rosman J, Widmann P: Antihypertensive agents, serum lipoproteins and glucose metabolism. Am J Cardiol 1991;67:26B-35B.
5. Sever P: The continuing challenge of hypertension. J Hum Hypertens 1995;9(suppl 2):49-51.
6. Guidelines for the Management of Mild Hypertension. Memorandum from a World Health Organization/International Society of Hypertension Meeting. Hypertension 1993;22: 392-403.
7. Waeber B, Brunner HR: Angiotensin II antagonists: A new class of antihypertensive agents. Br J Clin Pract 1996;50:265-268.
8. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, Lakshman R, Gottdiener J, Ramirez EA, Henderson WG: Single-drug therapy for hypertension in men. N Engl J Med 1993;328: 914-921.
9. Materson BJ, Reda DJ, Preston RA, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, Lakshman R, Gottdiener J, Ramirez EA, Henderson WG, for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents: Response to a second single antihypertensive agent used as monotherapy for hypertension after failure of the initial drug. Arch Intern Med 1995;155: 1757-1762.
10. Hansson L, Zanchetti A, for the HOT Study Group: The Hypertension Optimal Treatment (HOT) Study - Patient characteristics: Randomization, risk profiles, and early blood pressure results. Blood Press 1994;3:322-327.
11. Brunner HR, Ménard J, Waeber B, Burnier M, Biollaz J, Nussberger J, Bellet M: Treating the individual hypertensive patient: Considerations on dose, sequential monotherapy and fixed-dose combinations. J Hypertens 1990;8: 3-11.
12. Waeber B, Brunner HR: Low-dose combinations versus monotherapies in the treatment of hypertension. J Hypertens 1997;15(suppl 2): 17-20.
13. Furberg CD, Psaty BM, Meyer JV: Nifedipine: Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92:1326-1331.
14. Epstein M: Calcium antagonists: Still appropriate as first line antihypertensive agents. Am J Hypertens 1996;9:110-121.
15. Conti RC: Re-examining the clinical safety and roles of calcium antagonists in cardiovascular medicine. Am J Cardiol 1997;78(suppl 9A): 13-18.
16. Clozel JP: Pharmacology of the new calcium antagonist mibefradil. J Cardiovasc Pharmacol 1996:27(suppl A):17-21.
17. Ménard J, Chatellier G: Limiting factors in the control of blood pressure: Why is there a gap between theory and practice. J Hum Hypertens 1995;9(suppl 2):19-23.
18. Burt VL, Cutler JA, Higgins M, Horan M, Labarthe D, Whelton PK, Brown C, Rocella EJ: Trends in prevalence, awareness, treatment and control of hypertension in the adult US population: Data from the health examination surveys 1960-1991. Hypertension 1995;26: 60-69.
19. Isles CG, Walker LM, Beevers GD: Mortality in patients of the Glasgow Blood Pressure Clinic. J Hypertens 1986;4:141-156.
20. Fenichel RR, Lipicky RJ: Combination products as first-line pharmacotherapy. Arch Intern Med 1994;154:1429-1430.
21. Clozel JP, Osterrieder W, Kleinbloesem CH, Welker HA, Schlappi B, Tudor R, Hefti F, Schmitt R, Eggers H: Ro 40-5967: A new non-dihydropyridine calcium antagonist. Cardiovasc Drug Rev 1991;9:4-17.
22. Bernink PJLM, Prager G, Schelling A, Kobrin I, on behalf of the Mibefradil International Study Group: Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967). A new generation of calcium antagonists? Hypertension 1996;27(part 1):426-432.
23. Oparil S, Kobrin I, Abernethy DR, Levine BS, Reif MC, Shepherd AM: Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension. Am J Hypertens 1997;10:735-742.
24. Cruickshank JM, Thorp JM, Zacharias FJ: Benefits and potential harm of lowering high blood pressure. Lancet 1987;i:581-584.
25. Reid JL, Petrie JR, Glen SK, Meredith PA, Elliott HL: Clinical pharmacology of the novel calcium antagonist mibefradil. J Cardiovasc Pharmacol 1996;27(suppl A):22-26.
26. Lacourcière Y, Poirier L, Lefebvre J, Archambault F, Ave SD, Card C, Lindberg E: The anthihypertensive efficacy of the novel calcium antagonist mibefradil in comparison with nifedipine GITS in moderate to severe hypertensives with ambulatory hypertension. Am J Hypertens 1997;10:189-196.
27. Viskoper RJ, Bernink PJLM, Schelling A, Ribeiro AB, Kantola IM, Wilkins MR, Kobrin I: A randomized, double-blind trial comparing mibefradil and amlodipine: Two long-acting calcium antagonists with similar efficacy but different tolerability profiles. J Hum Hypertens 1997;11:387-393.
28. Massie BM, Chrysant SG, Jain A, Weir M, Weiss R, Kobrin I: Antihypertensive effects of mibefradil: A double-blind comparison with diltiazem CD. Clin Cardiol 1997;20:562-568.
29. Bakx AL, van der Wall EE, Braun S, Emanuelsson H, Bruschke AV, Kobrin I: Effects of the new calcium antagonist mibefradil (Ro40-5967) on excercise duration in patients with chronic stable angina pectoris: A multicenter, placebo-controlled study. Am Heart J 1995; 130:748-757.
30. Braun S, van der Wall EE, Emanuelsson H, Kobrin I: Effects of a new calcium antagonist (Ro40-5967), on silent ischemia in patients with stable chronic angina pectoris: A multicenter placebo-controlled study. J Am Coll Cardiol 1996;27:317-322.
31. Gillum RF, Makuc DM, Feldam JJ: Pulse rate, coronary heart disease, and death: The NHANES I epidemiologic follow-up study. Am Heart J 1991;121:172-177.
32. Dyer AR, Persky V, Stamler J, Paul O, Shekelle RB, Berkson DM, Leppa M, Schoenberger JA, Lindberg HA: Heart rate as a prognostic factor for coronary heart disease and mortality: Findings in three Chicago epidemiologic studies. Am J Epidemiol 1980;112:736-749.
33. Gillman MW, Kannel WB, Belanger A, D'Agostino RB: Influence of heart rate on mortality among persons with hypertension: The Framingham Study. Am Heart J 1993;125: 1148-1154.
34. Kobrin I, Charlon V: Predictable clinical effects in the treatment of hypertension and chronic, stable angina pectoris: Clinical studies of mibefradil. J Hypertens 1997;15(suppl 3): 35-40.